Key clinical point: Liver transplantation using HCV+ grafts to HCV– recipients resulted in “excellent short-term outcomes.”
Major finding: None of the recipients of grafts from nonviremic grafts had viremia. All 20 patients who received viremic grafts developed viremia, but completed treatment and achieved SVR.
Study details: The prospective, multicenter trial assessed 34 HCV– liver transplant recipients who received grafts from HCV+ donors (20 HCV viremic and 14 nonviremic).
Disclosures: The study was funded in part by the McIver Estate Young Investigator Benefactor Award. The authors reported they had no potential conflicts.
Aquel B et al. J Hepatol. 2020 Nov 11. doi: 10.1016/j.jhep.2020.11.005.